Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

WALTHAM, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. The grants are comprised of $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF). The grants will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.

"We are very pleased to receive support from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Foundation and the National Ataxia Foundation, national organizations recognized for their commitment to innovative research aimed at providing new therapeutic options for patients," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We believe that establishing partnerships with these non-profit organizations will result in a number of mutual benefits as the program matures and we prepare for human clinical trials."

Friedreich's ataxia is an inherited neurodegenerative disease in which a single gene defect results in inadequate production of the protein frataxin, leading to progressive damage to the nervous system and loss of muscle function. Prior research has demonstrated that production of frataxin protein can be increased in tissue samples and animal models by a family of compounds, suggesting the potential utility of these compounds in slowing or halting disease progression.

In April 2007, Re
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
(Date:5/20/2015)... Mulhouse, France, Cambridge, MA (PRWEB) May 20, 2015 ... of high quality transporter assay services for Drug-Drug ... Pharmacology, and Rhenovia Pharma, a world leader in ... using Translational Quantitative Systems Pharmacology supported by biosimulation, ... agreement. , The agreement allows both companies to ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... Wisconsin can create a dynamic, creative economy in its ... "welfare state" mentality, the leader of RedPrairie Corp. ... Jazwiec, who earlier this year made headlines when he ... were radical thoughts before an Economic Trends Breakfast of ...
... heard of identity theft (IDT), yet unless you have been ... risk. An alarming figure is that over half of the ... of business, employer, or other entity (not-for-profit or local, state, ... required under one or more federal and state laws to ...
... N.H. - American angel investors continue to be the ... investing $12.7 billion in the first half of 2006, an ... according to the Center for Venture Research at the ... has been conducting research on the angel market since 1980, ...
Cached Biology Technology:RedPrairie exec calls for 50 percent tax cut 2RedPrairie exec calls for 50 percent tax cut 3RedPrairie exec calls for 50 percent tax cut 4Identity theft: The business time bomb 2Identity theft: The business time bomb 3Identity theft: The business time bomb 4Angel investors commit $12.7B in first half of `06 2
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... On the second anniversary of the Deepwater ... is providing new insight into what happened in the disaster, ... such events in the future, and why existing tools were ... study, produced by the Gulf Oil Spill Ecotox Working Group ...
... from Cleveland Clinic,s Wellness Institute and Harvard University have ... is associated with a higher risk of stroke. Conversely, ... a lower risk. The study recently published ... is the first to examine soda,s effect on ...
... On the second anniversary of the Deepwater Horizon blowout, ... scientist Samantha Joye is urging the federal government to reassess ... occur in the future. The 22 researchers, whose paper ... , noted that the 2010 Deepwater Horizon oil spill was ...
Cached Biology News:NCEAS researchers offer new ecological model for deep-water oil spills 2NCEAS researchers offer new ecological model for deep-water oil spills 3Study finds soda consumption increases overall stroke risk 2Marine scientists urge government to reassess oil spill response 2Marine scientists urge government to reassess oil spill response 3Marine scientists urge government to reassess oil spill response 4
... Mouse polyclonal antibody raised against ... Immunogen: ZFHX4 ... a.a) partial recombinant protein with ... Accession Number: NM_024721 ...
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Through its SpliceArray service, ExonHit can ... events starting with your gene list. ... events and design microarray probes from high ... genome. Each splice event contained in a ...
... DNA Visualizer DX's sensitivity of DNA detection has ... band in an agarose gel can be detected ... kit can be purified by organic solvent extraction ... commercially kits worked well.) DNA excised from ...
Biology Products: